Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes
Primary result · Days 7 and 10Result — go to the resultCIns.max lower with LY900027 ≈14%-23%Authors' conclusion
The pharmacokinetics of insulin changed over catheter wear time even when an anti-inflammatory agent was present. Postprandial glycemic control was adversely affected by the accelerated insulin absorption and decreased insulin exposure.
Study context
- Population
- Adults with T1D for ≥1 year on stable continuous subcutaneous insulin infusion (CSII) for ≥3 monthsrandomized
- Participants
- 20 adults
- Comparison
- LY900027 vs insulin lispro over 10 days of CSII at one site
- Primary endpoint
- AUC of insulin lispro 0–5 h (AUCIns.0-5h) after bolus before MMTT and maximum observed insulin lispro concentration (CIns.max) on days 5, 7 and 10 vs day 3 (baseline)
- Follow-up
- Days 5, 7 and 10 vs day 3
Methodological detailsphase 1, double-blind, single-centre, two-way crossover
- Phase 1
- Double-blind
- Single-centre
- Two-way crossover
Primary result
Days 7 and 10
CIns.max lower with LY900027
≈14%-23%
P ≤ 0.0805
As reported in the abstract
- AUCIns.0-5h change day 10 vs day 3, LY900027
- −19%
- AUCIns.0-5h change day 10 vs day 3, insulin lispro
- −14%
- CIns.max increase days 5, 7, 10 vs day 3, LY900027
- ≈14%-23%
- CIns.max increase days 5, 7, 10 vs day 3, insulin lispro
- ≈16%-51%
Further findings
- Insulin absorption accelerated with both treatments from days 1 to 7
- Accelerated absorption and modest loss of total insulin exposure led to loss of mixed-meal tolerance test (MMTT) glycaemic control at later time points
Original publication
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. J Diabetes Sci Technol. Published 28 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →